Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20043088 | 0.76 | STAT3 (0.50) | PDE10AKMT2A | |
| SCHEMBL22095064 | 0.75 | CYSLTR1 (0.40) | GABRA1GABRB2HSD17B10PDE10A | |
| SCHEMBL18369635 | 0.74 | PDE2A (0.46) | GRM1HSD17B10PSMB5PDE10APDE2A | |
| SCHEMBL22095341 | 0.73 | GRM1 (0.47) | GRM1HSD17B10 | |
| SCHEMBL10088547 | 0.72 | GABRA1 (0.47) | GABRA1GABRB2HSD17B10 | |
| SCHEMBL14137820 | 0.71 | KMT2A (0.50) | HSD17B10MEN1KMT2A | |
| SCHEMBL3437609 | 0.71 | HSD17B10 (0.53) | HSD17B10PDE10APDE2AMEN1KMT2A | |
| SCHEMBL25820094 | 0.70 | SLC22A12 (0.42) | GABRA1GABRB2MAOADYRK1A | |
| SCHEMBL554539 | 0.68 | CYP1A2 (0.57) | HSD17B10PDE10APDE2A | |
| SCHEMBL31428884 | 0.68 | CYP1A2 (0.57) | HSD17B10PDE10APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291504-B2 | Small molecule inhibition of sulfotransferase SULT1A3 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-05-06 | — | — | US | disclosed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2020123482-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123482-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | GRM1 4114/4885GABRA1 1546/4885GABRB2 1430/4885 |
| US-12291504-B2 | Small molecule inhibition of sulfotransferase SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | GRM1 4114/4885GABRA1 1546/4885GABRB2 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.